The short answer
Randomised human data exists and is better than for most compounds in this catalogue, including trials published in Cell Metabolism, Science and GeroScience. Every one of them used a precursor rather than NAD+ itself, and the endpoints are largely biomarkers rather than clinical outcomes.
Key facts
- NADPARK
- Randomised phase I, NR, Parkinson's, Cell Metab 2022
- Orr 2024
- Randomised placebo-controlled, NR, older adults
- Yoshino 2021
- NMN, muscle insulin sensitivity, Science
- Yi 2023
- NMN efficacy and safety, GeroScience
- Compound used
- Precursors in all of them
- Dominant endpoints
- Biomarkers, not outcomes
NADPARK
Brakedal and colleagues published a randomised phase I trial of nicotinamide riboside supplementation in Parkinson's disease in Cell Metabolism in 2022. Phase I means the primary questions were safety and whether the intervention did what it was supposed to biologically, not whether it helped. Choosing Parkinson's reflects a specific mitochondrial hypothesis rather than a general ageing one.
Orr 2024
A randomised placebo-controlled trial of nicotinamide riboside in older adults, published in GeroScience in 2024. Placebo-controlled and randomised is the right design, and the population is the one the ageing hypothesis actually concerns. It is a real contribution, and it is modest in scale.
Research material referenced
NAD+ 500mg, third-party HPLC tested
Yoshino 2021
Published in Science in 2021, reporting that nicotinamide mononucleotide increased muscle insulin sensitivity in prediabetic women. Publication in Science reflects a notable result, and the endpoint (insulin sensitivity) is more physiological than a simple NAD+ level. It is one trial in one specific population.
The pattern across all of them
Precursors, not NAD+. Biomarker and mechanism endpoints more than clinical outcomes. Modest sample sizes. Early phases. This is a field with real randomised evidence at an early stage, which is substantially better than most of this catalogue and substantially short of what the surrounding commentary implies.
What is conspicuously absent
Large trials with hard clinical endpoints. Nothing here resembles the scale of the incretin programmes. TRIUMPH enrolled over 5,800 participants across multiple Phase 3 studies. NAD+ precursor research has produced good early evidence, not confirmatory evidence, and the difference is not a technicality.
And none of it concerns NAD+ as supplied here
The trials administered defined precursor preparations under clinical supervision with ethics approval. Material supplied for laboratory research is not those preparations and is not covered by those findings.
Frequently asked questions
Is there real human data on NAD+?
Yes. Randomised trials in Cell Metabolism, Science and GeroScience. All used precursors rather than NAD+ itself.
What did they measure?
Largely biomarkers and mechanism endpoints. Yoshino 2021 measured muscle insulin sensitivity, which is more physiological.
Is this strong evidence?
Real early-stage evidence, better than most of this catalogue. Not confirmatory. The trials are small and early-phase.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrakedal B et al., NADPARK. Cell Metab 2022 (PMID 35235774)pubmed.ncbi.nlm.nih.gov
- PubMedOrr ME et al. Geroscience 2024 (PMID 37994989)pubmed.ncbi.nlm.nih.gov
- PubMedYoshino M et al. Science 2021 (PMID 33888596)pubmed.ncbi.nlm.nih.gov
- PubMedYi L et al., Efficacy and safety of NMN supplementation. Geroscience 2023 (PMID 36482258)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- NAD+, NMN and NR: Three Points on One PathwayNot three competing compounds but three positions in a single conversion sequence. Which has the trial data, and which is hardest to deliver.
- NAD+ Storage: Different Chemistry, Different RisksNot a peptide, so peptide degradation logic does not apply. The bonds at risk are glycosidic and pyrophosphate, and both hydrolyse readily.
- NAD+ Regulatory StatusNo marketing authorisation as a medicine anywhere. Why a precursor's food supplement status proves nothing, and why ageing language is the real hazard here.
- Eighty Daltons Apart, and Metabolically OpposedNADP is NAD plus one phosphate - 743.4 against 663.4 Da. One drives catabolism, the other biosynthesis and antioxidant defence.
- Two Products in This Catalogue, One Connected SystemGlutathione reductase regenerates GSH from GSSG using NADPH. The antioxidant capacity of one molecule depends on the reduced pool of the other.